Magseed Pro(R)/ Sentimag(R) Gen3

A Prospective, Multi Center, International, Open Label Study of the Use of Magseed Pro(R) Markers and Sentimag(R) Gen3 to Localize Breast Lesions and Suspicious/Biopsy-proven Positive Lymph Nodes in Breast Cancer Patients

The purpose of this study is to provide prospective evidence that the Magseed Pro® marker /Sentimag® Gen3 system is safe and effective for marking A. suspicious/biopsy-proven positive axillary lymph nodes; and B. soft tissue lesions including cancer and pre-cancerous change in the breast

Study Overview

• Status: Recruiting
• Conditions: Breast Cancer
• Intervention / Treatment: Device: Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics

Detailed Description

The purpose of this study is to provide prospective evidence that the Magseed Pro® marker /Sentimag® Gen3 system is safe and effective for marking A. suspicious/biopsy-proven positive axillary lymph nodes; and B. soft tissue lesions including cancer and pre-cancerous change in the breast The devices used in this clinical trial are the Magseed Pro® marker and Sentimag® Gen3 system by Endomagnetics Limited.

The Endomag Magseed Pro® Marker System is intended to be placed within the target soft tissue prior to planned surgical removal. The marker, when used in conjunction with the Sentimag® Gen 3 System, can be used as a guide for the surgeon to follow in the excision of tissue. The Sentimag® Gen3 Magnetic Localisation System when used with the Magseed family of markers is indicated to assist in localising soft tissue lesions.

The study design is a multicentre international prospective, open label, study of Magseed Pro® marker and Sentimag® Gen3 system in patients with breast and/or lymph node pathology with:

A. axillary lymph nodes requiring localisation prior to surgical excision (suspicious and/or biopsy proven lymph node or other pathology indicating removal) and/or B. breast lesions requiring localisation

Patients will have the Magseed Pro® marker placed to mark A. surgical excision of suspicious/biopsy-proven axillary lymph node as part of a targeted lymph node biopsy procedure AND/OR B. breast lesions in patients undergoing surgical excision of the targeted breast lesion The Magseed Pro® marker will be localised using the Sentimag® Gen3 system and therafter surgically removed with the target tissue.

This study will enrol 224 patients; 112 with Magseed Pro® marker placed to mark breast lesions and 112 with Magseed Pro® marker placed to mark nodes.

The expected duration of enrolment is approximately 9 months across all sites with each individual subject's participation lasting approximately 1-38 weeks after enrolment.

• Study Type: Interventional
• Enrollment (Estimated): 224
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Matt Womack, Dr; Phone Number: +447851247439; Email: mwomack@endomag.com
• Study Contact Backup: Name: Tanja Odeneg, Dr; Phone Number: +441223652604; Email: todeneg@endomag.com

Study Locations

• Germany
  • Bottrop, Germany
    • Recruiting
    • Marienhospital Bottrop GmbH
    • Contact: Hans Christian Kolberg
  • Frankfurt, Germany
    • Recruiting
    • AGAPLESION Markus Frankfurter Diakonie Kliniken gGmbH
    • Contact: Marc Thill
  • Munich, Germany
    • Not yet recruiting
    • Technical University Munich
    • Contact: Stefan Paepke
• United Kingdom
  • London, United Kingdom
    • Recruiting
    • Royal Marsden Hospital
    • Contact: Peter Barry
  • London, United Kingdom
    • Recruiting
    • Guy's Hospital
    • Contact: Ashutosh Kothari
  • Manchester, United Kingdom
    • Recruiting
    • University Hospital South Manchester
    • Contact: James Harvey

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participant is willing and able to give informed consent for participation in the study
• Participant is aged 18 years or older at the time of consent.
• Patients requiring breast lesion/axillary node marking and excision

Exclusion Criteria:• Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period. A pregnancy test is required for all women of childbearing potential within 7 days before enrolment.

• Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical trial or to comply with follow up requirements, or impact the scientific soundness of the clinical trial results
• Known hypersensitivity to Nitinol
• Subject has current active infection at the implantation site in the breast (per investigator discretion)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: axillary lymph nodes requiring localisation prior to surgical excision; The Magseed Pro® marker is intended to be placed percutaneously in suspicious/biopsy proven positive axillary lymph nodes under imaging guidance to mark tissue intended for selective surgical removal. The Magseed Pro® marker is localised using the Sentimag® Gen3 system handheld probes and surgically removed within/from the target tissue.	Device: Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics; placement of Magseed Pro & localisation with Sentimag Gen3 in axillary lymph nodes and/or breast lesions
Other: breast lesions requiring localisation; The Magseed Pro® marker is intended to be placed percutaneously in breast lesions under imaging guidance to mark tissue intended for selective surgical removal. The Magseed Pro® marker is localised using the Sentimag® Gen3 system handheld probes and surgically removed within/from the target tissue.	Device: Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics; placement of Magseed Pro & localisation with Sentimag Gen3 in axillary lymph nodes and/or breast lesions

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The primary endpoints are the retrieval rates of the Magseed Pro® marker with the target lesion within the initial excised specimen for A.) axillary lymph nodes B.) breast lesions A.) axillary lymph nodes. B.) breast lesions	This is defined as the number of patients with successful Magseed Pro® marker placement as demonstrated on imaging, in whom the Magseed Pro® marker and the associated lymph node and/ or lesion is retrieved, divided by the total number of subjects.	time of surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tissue response (unexpected and expected)	EXPECTED Early (up to 2 days) - acute inflammation in the form of neutrophils with lymphocytes and some associated haemorrhage. Late (>2 days) - active chronic inflammation in the form of neutrophils, lymphocytes, macrophages together with a fibroblastic response. Likely a foreign body reaction with increased numbers of histiocytes and some multinucleated giant cells. Possible granuloma formation (foreign body type). Scattered eosinophils. Later scarring (after 1-2 weeks) with fibrosis. Possible fat necrosis. UNEXPECTED Early and Late - • Very florid fibroblastic response with granulation tissue formation that mimics malignancy (nodular fasciitis-like), which may need immunohistochemical tests to differentiate between reactive chan	time of surgery
Presence of unexpected histological tissue response for short- and long-term use of Magseed Pro marker	UNEXPECTED HISTOLOGICAL RESPONSE Early and Late - • Very florid fibroblastic response with granulation tissue formation that mimics malignancy (nodular fasciitis-like), which may need immunohistochemical tests to differentiate between reactive chan	time of surgery
Rate of device-related AE's and SAE's	Rate of device-related AE's and SAE's	through study completion, an average of 38 weeks
Retrieval rate for all lesions	Retrieval rate for all lesions (including target, non-target lesions and multiple lesions per patient) out of the total number of lesions with a Magseed Pro® marker placement. Non-target lesions include additional marked lesions which weren't defined as the target for the primary endpoint and any marked lesions from patients undergoing long term node retrieval.	time of surgery
Retrieval rate for all nodes	Retrieval rate for all nodes (including multiple nodes per patient where applicable) out of the total number of nodes with a Magseed Pro® marker placement.	time of surgery
Per lesion retrieval rate for target excised specimens	Per lesion retrieval rate for target excised specimens	time of surgery
Per lesion retrieval rate for all excised specimens	Per lesion retrieval rate for all excised specimens	time of surgery
Per lesion retrieval rate for all lesion	Per lesion retrieval rate for all lesion	time of surgery
Per lesion retrieval rate for all nodes	Per lesion retrieval rate for all nodes	time of surgery
Per patient retrieval rate for Magseed Pro® marker placed prior to neo-adjuvant therapy and retrieved post neo-adjuvant therapy	Per patient retrieval rate for Magseed Pro® marker placed prior to neo-adjuvant therapy and retrieved post neo-adjuvant therapy	time of surgery
Per lesion retrieval rate for Magseed Pro® marker placed prior to neo-adjuvant therapy and retrieved post neo-adjuvant therapy.	Per lesion retrieval rate for Magseed Pro® marker placed prior to neo-adjuvant therapy and retrieved post neo-adjuvant therapy.	time of surgery
Per patient retrieval rate for Magseed Pro® marker where retrieval surgery is within 30 days of placement.	Per patient retrieval rate for Magseed Pro® marker where retrieval surgery is within 30 days of placement.	time of surgery
Per lesion retrieval rate for Magseed Pro® marker where retrieval surgery is within 30 days of placement.	Per lesion retrieval rate for Magseed Pro® marker where retrieval surgery is within 30 days of placement.	time of surgery
Per patient retrieval rate for Magseed Pro® marker where retrieval surgery is greater than 30 days after placement	Per patient retrieval rate for Magseed Pro® marker where retrieval surgery is greater than 30 days after placement	time of surgery
Per lesion retrieval rate for Magseed Pro® marker where retrieval surgery is greater than 30 days after placement.	Per lesion retrieval rate for Magseed Pro® marker where retrieval surgery is greater than 30 days after placement.	time of surgery
Per lesion retrieval rate for target excised specimens (i.e., lesions plus nodes) where Magtrace® Tracer is present in the target node or in the region of the target lesion.	Per lesion retrieval rate for target excised specimens (i.e., lesions plus nodes) where Magtrace® Tracer is present in the target node or in the region of the target lesion.	time of surgery
Per lesion retrieval rate for all excised specimens (i.e., lesions plus nodes) where Magtrace® Tracer is present in the target node or in the region of the target lesion.	Per lesion retrieval rate for all excised specimens (i.e., lesions plus nodes) where Magtrace® Tracer is present in the target node or in the region of the target lesion.	time of surgery
Per lesion retrieval rate for target lesions where Magtrace® Tracer is present in the region of the target lesion.	Per lesion retrieval rate for target lesions where Magtrace® Tracer is present in the region of the target lesion.	time of surgery
Per lesion retrieval rate for all lesions where Magtrace® Tracer is present in the region of the lesion.	Per lesion retrieval rate for all lesions where Magtrace® Tracer is present in the region of the lesion.	time of surgery
Per node retrieval rate for target nodes where Magtrace® Tracer is present in the target node.	Per node retrieval rate for target nodes where Magtrace® Tracer is present in the target node.	time of surgery
Per node retrieval rate for all nodes where Magtrace® Tracer is present in the node.	er node retrieval rate for all nodes where Magtrace® Tracer is present in the node.	time of surgery
Interventionist rated ease of Magseed Pro® marker placement by the interventionist	5 point Likert scale, very easy = 5, very difficult = 1	seed placement
Rate of deployment failure	A Magseed Pro is not deployed from the needle, or is accidentally deployed prior to use in the patient • Success rate of seed placement: Accurate: Within the breast lesion or clipped lymph node. For lesions less than 5 mm in size the marker may not necessarily be within the excised specimen but should be within 10mm1 of the lesion.; Inadequate: Not in the targeted lesion or clipped lymph node determined by placement imaging requiring additional marker placement	seed placement
Surgeon rated ease of intra-operative localisation	5 point Likert scalevery easy = 5, very difficult = 1	time of surgery
Magtrace® Tracer counts for excised lymph nodes during SLNB procedures	Magtrace® Tracer counts for excised lymph nodes during SLNB procedures	time of surgery
Re-excision rate (i.e., second procedure required). With reason for second procedure.	Re-excision rate (i.e., second procedure required). With reason for second procedure.	time of surgery
Success rate of maintained marker position at the time of removal as determined by specimen X-ray and or Sentimag Gen3 system.	Accurate: Magseed Pro® marker within the target lesion or marked lymph node.; Inadequate: Magseed Pro® marker not within the target lesion or marked lymph node	time of surgery

Collaborators and Investigators

• Sponsor: Endomagnetics Ltd.
• Investigators: Principal Investigator: Stefan Paepke, Dr, The technical university of Munich

Study record dates

Study Major Dates

• Study Start (Actual): March 2, 2023
• Primary Completion (Estimated): December 31, 2024
• Study Completion (Estimated): June 30, 2025

Study Registration Dates

• First Submitted: November 8, 2021
• First Submitted That Met QC Criteria: December 1, 2021
• First Posted (Actual): December 3, 2021

Study Record Updates

• Last Update Posted (Actual): August 12, 2024
• Last Update Submitted That Met QC Criteria: August 9, 2024
• Last Verified: August 1, 2024

More Information

Terms related to this study

• Keywords: Magseed Pro; Sentimag Gen3
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms
• Other Study ID Numbers: EU001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No